Оксана Валерьевна Глоба
Оксана Валерьевна Глоба has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Lyudmila Mikhailovna Kuzenkova
National Medical Research Center for Children's Health, Ministry of Health of Russia
8 shared publications - Kirill Victorovich Savostyanov
National Medical Research Center for Children’s Health, Moscow, Russia
7 shared publications - Aleksander Alekseevich Pushkov
National Medical Research Center for Children’s Health, Ministry of Health of Russian Federation
4 shared publications - Алексей Львович Куренков
National Medical Research Center for Children’s Health, Ministry of Health of the Russian Federation
4 shared publications - Дарья Сергеевна Николенко
National Medical Research Center for Children’s Health
4 shared publications - Луизат Муслимовна Абдуллаева
National Medical Research Center for Children’s Health, Ministry of Health of Russia
4 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 74-87
Results of a Two-Year Comprehensive Follow-Up of Patients with Spinal Muscular Atrophy Type I Who Received Gene Therapy with Onasemnogen Abeparvovek
Introduction . Spinal muscular atrophy (SMA) is among the most severe inherited neuromuscular diseases. The development of pathogenetic treatment methods, including gene therapy, and their widespread clinical adoption has ushered in a new era in SMA treatment, making it possible not only to halt the progression of the disease but also to improve patients’ functional capabilities. Aim : to evaluate the efficacy of gene therapy in a real-world clinical practice with a 2-year follow-up study of patients with SMA type I who received treatment with onasemnogene abeparvovec. Materials and methods . The study included 73 patients with SMA type I. The disease was confirmed by molecular genetic testing.The diagnosis of SMA type I in 22 patients (30.1%) was established due to the development of the clinical picture of the disease and after confirmatory DNA diagnostics. In 51 patients (69.9%), initially identified as part of expanded neonatal screening, the diagnosis was established immediately after the onset of the first SMA symptoms. The mean age at the time of gene therapy was 2.78±1.87 months (95% CI 2.35–3.22), min 1.00, max 7.00. A comprehensive assessment of treatment effectiveness included clinical (the main the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores) and electroneuromyographic (latency, amplitude and area of the negative peak of the distal compound muscle action potential during electrical stimulation of the ulnar nerve at the wrist, the motor nerve conduction velocity of the ulnar nerve on the forearm) parameters before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results . Following gene therapy, a large number of patients with SMA type I were able to achieve basic motor skills: 42.5% had good head control in the prone position; 78.1% rolled over from a supine to prone position; 47.2% sitting without support; 31.9% standing with assistance; 23.2% hands-&-knees crawling; 20.0% walking with assistance; 13.2% standing alone; 5.7% walking alone. However, most patients reached motor development milestones later than the WHO standards. By the end of the observation period, the HINE-2 score in patients with SMA type I significantly increased and amounted to Me 18.50 (16.00–24.00) points, with three children achieving the maximum score. The CHOP-INTEND scale score also increased significantly and amounted to Me 60.00 (58.00–64.00) points by the end of the 2-year observation period, with 17 children (23.3%) achieving the maximum score. Before gene therapy, patients with type I SMA had low values of the amplitude [Me 0.32 mV (0.15–0.81)] and area [Me 0.80 ms×mV (0.36–1.70)] of the compound muscle action potential. 24 months after gene therapy, the values of the amplitude and area significantly increased [Me 0.80 mV (0.60–1.20) and Me 1.40 ms×mV (1.00–2.10), respectively]. However, they did not reach the electroneuromyographic values of children without neurological pathology. During clinical and electroneuromyographic assessment in the dynamics of 2-year follow-up, it was not possible to establish statistically significant differences in patients with SMA type I depending on the onset of expanded neonatal screening. Conclusion . Gene therapy in patients with SMA type I results in significant improvements in motor development. Despite persistent delays in motor skill development, a large number of patients achieved key milestones in early motor development, as demonstrated by significant increases in HINE-2 and CHOP-INTEND scores and improved electroneuromyographic parameters.
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 74-87
Open AccessResults of a Two-Year Comprehensive Follow-Up of Patients with Spinal Muscular Atrophy Type I Who Received Gene Therapy with Onasemnogen Abeparvovek
Introduction . Spinal muscular atrophy (SMA) is among the most severe inherited neuromuscular diseases. The development of pathogenetic treatment methods, including gene therapy, and their widespread clinical adoption has ushered in a new era in SMA treatment, making it possible not only to halt the progression of the disease but also to improve patients’ functional capabilities. Aim : to evaluate the efficacy of gene therapy in a real-world clinical practice with a 2-year follow-up study of patients with SMA type I who received treatment with onasemnogene abeparvovec. Materials and methods . The study included 73 patients with SMA type I. The disease was confirmed by molecular genetic testing.The diagnosis of SMA type I in 22 patients (30.1%) was established due to the development of the clinical picture of the disease and after confirmatory DNA diagnostics. In 51 patients (69.9%), initially identified as part of expanded neonatal screening, the diagnosis was established immediately after the onset of the first SMA symptoms. The mean age at the time of gene therapy was 2.78±1.87 months (95% CI 2.35–3.22), min 1.00, max 7.00. A comprehensive assessment of treatment effectiveness included clinical (the main the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores) and electroneuromyographic (latency, amplitude and area of the negative peak of the distal compound muscle action potential during electrical stimulation of the ulnar nerve at the wrist, the motor nerve conduction velocity of the ulnar nerve on the forearm) parameters before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results . Following gene therapy, a large number of patients with SMA type I were able to achieve basic motor skills: 42.5% had good head control in the prone position; 78.1% rolled over from a supine to prone position; 47.2% sitting without support; 31.9% standing with assistance; 23.2% hands-&-knees crawling; 20.0% walking with assistance; 13.2% standing alone; 5.7% walking alone. However, most patients reached motor development milestones later than the WHO standards. By the end of the observation period, the HINE-2 score in patients with SMA type I significantly increased and amounted to Me 18.50 (16.00–24.00) points, with three children achieving the maximum score. The CHOP-INTEND scale score also increased significantly and amounted to Me 60.00 (58.00–64.00) points by the end of the 2-year observation period, with 17 children (23.3%) achieving the maximum score. Before gene therapy, patients with type I SMA had low values of the amplitude [Me 0.32 mV (0.15–0.81)] and area [Me 0.80 ms×mV (0.36–1.70)] of the compound muscle action potential. 24 months after gene therapy, the values of the amplitude and area significantly increased [Me 0.80 mV (0.60–1.20) and Me 1.40 ms×mV (1.00–2.10), respectively]. However, they did not reach the electroneuromyographic values of children without neurological pathology. During clinical and electroneuromyographic assessment in the dynamics of 2-year follow-up, it was not possible to establish statistically significant differences in patients with SMA type I depending on the onset of expanded neonatal screening. Conclusion . Gene therapy in patients with SMA type I results in significant improvements in motor development. Despite persistent delays in motor skill development, a large number of patients achieved key milestones in early motor development, as demonstrated by significant increases in HINE-2 and CHOP-INTEND scores and improved electroneuromyographic parameters.
- Open Access
- 29 April 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (1) , 60-68
Dilated cardiomyopathy in the structure of a familial form of TOP3A-related Bloom-like syndrome
Bloom-like syndrome is a rare autosomal recessive disorder caused by nucleotide variants in the TOP3A gene. It is characterized by clinical manifestations similar to Bloom syndrome, including a characteristic facial phenotype and physical development delay, but diff ers in the more frequent development of a dilated cardiomyopathy. These syndromes belong to the group of hereditary diseases associated by impaired DNA repair. Given the existence of isolated clinical cases with a predominant description of characteristic physical development delay, a detailed description of the course of dilated cardiomyopathy is signifi cant for understanding the disease and optimizing medical treatment. Here is a description of the clinical course and features of the child’s management with a homozygous mutation c.2264_2265delinsT in the TOP3A gene, examined at the cardiology department of the National Medical Research Center of Children’s Health of the Ministry Health of the Russian Federation. An analysis of anamnesis data, including family history, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic testing performed using Sanger direct sequencing technology, was conducted. A literature review of patients with mutations in the TOP3A gene was conducted. The presented clinical case demonstrates the importance of timely diagnosis of the disease, the high frequency of cardiac manifestations, particularly the steadily progressive and fatal course of dilated cardiomyopathy. In childhood, dilated cardiomyopathy can be a dominant and life-threatening manifestation of TOP3A -associated Bloom-like syndrome. Given the risk of a sudden and aggressive course of dilated cardiomyopathy, identifying mutations in the TOP3A gene in children with physical development delay and a characteristic «bird-like» facies has important prognostic value. Improving the prognosis requires early diagnosis, including prenatal diagnosis in high-risk families, the development of pathogenetic therapy, and a multidisciplinary approach to patient management.
- 29 April 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (1) , 60-68
Open AccessDilated cardiomyopathy in the structure of a familial form of TOP3A-related Bloom-like syndrome
Bloom-like syndrome is a rare autosomal recessive disorder caused by nucleotide variants in the TOP3A gene. It is characterized by clinical manifestations similar to Bloom syndrome, including a characteristic facial phenotype and physical development delay, but diff ers in the more frequent development of a dilated cardiomyopathy. These syndromes belong to the group of hereditary diseases associated by impaired DNA repair. Given the existence of isolated clinical cases with a predominant description of characteristic physical development delay, a detailed description of the course of dilated cardiomyopathy is signifi cant for understanding the disease and optimizing medical treatment. Here is a description of the clinical course and features of the child’s management with a homozygous mutation c.2264_2265delinsT in the TOP3A gene, examined at the cardiology department of the National Medical Research Center of Children’s Health of the Ministry Health of the Russian Federation. An analysis of anamnesis data, including family history, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic testing performed using Sanger direct sequencing technology, was conducted. A literature review of patients with mutations in the TOP3A gene was conducted. The presented clinical case demonstrates the importance of timely diagnosis of the disease, the high frequency of cardiac manifestations, particularly the steadily progressive and fatal course of dilated cardiomyopathy. In childhood, dilated cardiomyopathy can be a dominant and life-threatening manifestation of TOP3A -associated Bloom-like syndrome. Given the risk of a sudden and aggressive course of dilated cardiomyopathy, identifying mutations in the TOP3A gene in children with physical development delay and a characteristic «bird-like» facies has important prognostic value. Improving the prognosis requires early diagnosis, including prenatal diagnosis in high-risk families, the development of pathogenetic therapy, and a multidisciplinary approach to patient management.
- Open Access
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 195-208
A single-center study of the clinical and genetic characteristics of the dilated cardiomyopathy caused by MYH7 gene variants in eighty unrelated children
Introduction. The dilated cardiomyopathy (DCM) represents a group of myocardial disorders whose primary characteristics are dilation of the left ventricular cavity and impaired systolic function. Thanks to significant progress in the field of molecular genetics, over fifty genes responsible for the primary form of DCM have now been identified, with mutations in the MYH7 gene accounting for up to 50% of all genetically confirmed cases. Objective: to establish the clinical and genetic characteristics of the dilated cardiomyopathy caused by mutations in the MYH7 gene in children.Materials and Methods. This study analyzed data from 250 DCM children examined at the Cardiology department of the National Medical Research Center for Children’s Health of the Ministry of Health from 2015 to 2024. The investigation employed modern molecular genetic diagnostic methods and comprehensive clinical and instrumental examination, with assessment of clinical dynamics over a 5-year period.Results. Isolated MYH7-associated DCM was confirmed in 80 (40,8%) unrelated children with identified causative variants. The clinical characteristics of the disease include early onset (over 80% of cases manifesting within the first year of life), frequent combination with non-compaction of the myocardium (85%), and the development of left ventricular reverse remodeling following treatment.Variants in exons 19–23 were established to be associated with severe mitral regurgitation, requiring surgical intervention at an early age. In 3 cases, a rare combination of cardiomyopathy and myopathy was observed.Conclusion. The study confirms the significant role of pathogenic variants in the MYH7 gene in the development of cardiomyopathy in children. MYH7-associated forms of the disease with timely and appropriate drug therapy are characterized by a favorable prognosis, as evidenced by the high 5-year survival rate (97,4%) in patients. Molecular genetic testing is important in verifying the diagnosis, managing an early screening of relatives, and predicting the course of disease. The systematization of clinical and genetic characteristics creates the foundation for the devilment of personalized treatment approaches. A multidisciplinary approach to managing patients with cardiomyopathy and extracardiac manifestations is of particular importance.Compliance with ethical standards. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki of 1975 and was approved by the Local Ethics Committee of the National Medical Research Center for Children’s Health of the Ministry of Health of Russia (Protocol No. 10, dated August 28, 2020). Informed consent was obtained from all participants or their legal representatives.Contribution:Burykina Yu.S. — concept and design of the study, collection and processing of material, text editing;Sdvigova N.A. — concept and design of the study, collection and processing of material, text editing;Basargina E.N. — text editing;Globa O.V. — text editing;Kurenkov A.L. — text editing;Zhanin I.S. — text editing;Pushkov A.A. — collection and processing of material, text writing;Savostyanov K.V. — concept and design of the study, text editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Acknowledgements. The authors express their gratitude to the patients’ families for supporting our research. The authors would like to express their gratitude to MD, Professor A.P. Fisenko, Director of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for his support and technical assistance in implementation of this work. The authors would like to thank the entire staff of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for the opportunity of interdisciplinary approach to patients care.Received: October 8, 2025Accepted: December 1, 2025Published: January 31, 2026
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 195-208
Open AccessA single-center study of the clinical and genetic characteristics of the dilated cardiomyopathy caused by MYH7 gene variants in eighty unrelated children
Introduction. The dilated cardiomyopathy (DCM) represents a group of myocardial disorders whose primary characteristics are dilation of the left ventricular cavity and impaired systolic function. Thanks to significant progress in the field of molecular genetics, over fifty genes responsible for the primary form of DCM have now been identified, with mutations in the MYH7 gene accounting for up to 50% of all genetically confirmed cases. Objective: to establish the clinical and genetic characteristics of the dilated cardiomyopathy caused by mutations in the MYH7 gene in children.Materials and Methods. This study analyzed data from 250 DCM children examined at the Cardiology department of the National Medical Research Center for Children’s Health of the Ministry of Health from 2015 to 2024. The investigation employed modern molecular genetic diagnostic methods and comprehensive clinical and instrumental examination, with assessment of clinical dynamics over a 5-year period.Results. Isolated MYH7-associated DCM was confirmed in 80 (40,8%) unrelated children with identified causative variants. The clinical characteristics of the disease include early onset (over 80% of cases manifesting within the first year of life), frequent combination with non-compaction of the myocardium (85%), and the development of left ventricular reverse remodeling following treatment.Variants in exons 19–23 were established to be associated with severe mitral regurgitation, requiring surgical intervention at an early age. In 3 cases, a rare combination of cardiomyopathy and myopathy was observed.Conclusion. The study confirms the significant role of pathogenic variants in the MYH7 gene in the development of cardiomyopathy in children. MYH7-associated forms of the disease with timely and appropriate drug therapy are characterized by a favorable prognosis, as evidenced by the high 5-year survival rate (97,4%) in patients. Molecular genetic testing is important in verifying the diagnosis, managing an early screening of relatives, and predicting the course of disease. The systematization of clinical and genetic characteristics creates the foundation for the devilment of personalized treatment approaches. A multidisciplinary approach to managing patients with cardiomyopathy and extracardiac manifestations is of particular importance.Compliance with ethical standards. The study was conducted in accordance with the ethical standards of the Declaration of Helsinki of 1975 and was approved by the Local Ethics Committee of the National Medical Research Center for Children’s Health of the Ministry of Health of Russia (Protocol No. 10, dated August 28, 2020). Informed consent was obtained from all participants or their legal representatives.Contribution:Burykina Yu.S. — concept and design of the study, collection and processing of material, text editing;Sdvigova N.A. — concept and design of the study, collection and processing of material, text editing;Basargina E.N. — text editing;Globa O.V. — text editing;Kurenkov A.L. — text editing;Zhanin I.S. — text editing;Pushkov A.A. — collection and processing of material, text writing;Savostyanov K.V. — concept and design of the study, text editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Acknowledgements. The authors express their gratitude to the patients’ families for supporting our research. The authors would like to express their gratitude to MD, Professor A.P. Fisenko, Director of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for his support and technical assistance in implementation of this work. The authors would like to thank the entire staff of the National Medical Research Center for Children’s Health of the Ministry of Health of the Russian Federation for the opportunity of interdisciplinary approach to patients care.Received: October 8, 2025Accepted: December 1, 2025Published: January 31, 2026
- Open Access
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 182-194
Results of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease
Introduction. The use of gene therapy in patients with spinal muscular atrophy (SMA) has led to a significant improvement in the prognosis of motor development. The inclusion of SMA in the expanded neonatal screening in the Russian Federation allowed not only identifying patients as early as possible, but also gene therapy at the presymptomatic stage of the disease became available for some of them.Objective. To evaluate the effectiveness of gene therapy in real clinical practice during 2 years of follow-up of SMA patients treated with onasemnogen abeparvovec at the presymptomatic stage of the disease.Materials and methods. The study included thirty five SMA children, with a genetically verified diagnosis of SMA without developing symptoms of the disease. The diagnosis of SMA was established during the pilot project of the extended neonatal screening or from 01/01/2023 as part of the extended neonatal screening. The diagnosis was verified during DNA diagnostics. Deletion of exons 7 and/or 8 of the SMN1 gene in the homozygous state was detected in all children. All patients received gene therapy with onasemnogen abeparvovec, the average age at the time of therapy was 2.00 ± 0.94 months (95% CI 1.68–2.32), min — 1.00, max — 5.00. A comprehensive assessment was conducted of clinical (the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores), electroneuromyographic (latency, amplitude and area of the negative peak of the compound muscle action potential during electrical stimulation of the ulnar nerve on the wrist; the motor nerve conduction velocity of the ulnar nerve on the forearm) and biochemical parameters (levels of light and heavy chains of neurofilaments (NF) in blood serum in SMA patients at the presymptomatic stage before initiation of gene therapy and after 6, 12, 18, and 24 months after its implementation.Results. In our study, SMA patients at the presymptomatic stage, both before and after gene therapy, had motor development in accordance with age norms and did not significantly differ from children without neurological pathology. A comparative analysis of the electroneuromyographic parameters in SMA children and a group of healthy children revealed no statistically significant differences in patients at the presymptomatic stage of SMA on the background of gene therapy. A comparative analysis of the levels of light and heavy NF chains in the blood serum in SMA patients at the presymptomatic stage before gene therapy and 76 neurologically healthy children obtained in a recent study showed the level of light NF chains in SMA to be significantly higher (p < 0.001) — Me — 6.00, Q1; Q3 = 6.00; 31.43 pg/ml and Me — 4.00, Q1; Q3 = 2.50; 9.57 pg/ml, respectively. At the same time, the level of heavy NF chains did not significantly differ when comparing SMA patients at the presymptomatic stage before gene therapy with healthy peers. The use of onasemnogen abeparvovec in SMA patients at the presymptomatic stage led to a statistically significant decrease in the level of light chains NF in the blood serum. The maximum decrease in NF was observed 3–6 months after the gene therapy.Conclusion. Carrying out gene therapy using the onasemnogen abeparvovek in SMA patients at the presymptomatic stage made it possible to prevent the development of symptoms of the disease and achieve the main stages of motor development milestones according to WHO criteria.Compliance with ethical standards. Permission to conduct this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health (Minutes of the Local ethics committee, meeting No. 10 dated 10/06/2022).Contribution:Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A. — concept and design of research, writing, editing;Chernikov V.V. — statistical data processing, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: November 6, 2024Accepted: December 1, 2024Published: January 31, 2025
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 182-194
Open AccessResults of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease
Introduction. The use of gene therapy in patients with spinal muscular atrophy (SMA) has led to a significant improvement in the prognosis of motor development. The inclusion of SMA in the expanded neonatal screening in the Russian Federation allowed not only identifying patients as early as possible, but also gene therapy at the presymptomatic stage of the disease became available for some of them.Objective. To evaluate the effectiveness of gene therapy in real clinical practice during 2 years of follow-up of SMA patients treated with onasemnogen abeparvovec at the presymptomatic stage of the disease.Materials and methods. The study included thirty five SMA children, with a genetically verified diagnosis of SMA without developing symptoms of the disease. The diagnosis of SMA was established during the pilot project of the extended neonatal screening or from 01/01/2023 as part of the extended neonatal screening. The diagnosis was verified during DNA diagnostics. Deletion of exons 7 and/or 8 of the SMN1 gene in the homozygous state was detected in all children. All patients received gene therapy with onasemnogen abeparvovec, the average age at the time of therapy was 2.00 ± 0.94 months (95% CI 1.68–2.32), min — 1.00, max — 5.00. A comprehensive assessment was conducted of clinical (the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores), electroneuromyographic (latency, amplitude and area of the negative peak of the compound muscle action potential during electrical stimulation of the ulnar nerve on the wrist; the motor nerve conduction velocity of the ulnar nerve on the forearm) and biochemical parameters (levels of light and heavy chains of neurofilaments (NF) in blood serum in SMA patients at the presymptomatic stage before initiation of gene therapy and after 6, 12, 18, and 24 months after its implementation.Results. In our study, SMA patients at the presymptomatic stage, both before and after gene therapy, had motor development in accordance with age norms and did not significantly differ from children without neurological pathology. A comparative analysis of the electroneuromyographic parameters in SMA children and a group of healthy children revealed no statistically significant differences in patients at the presymptomatic stage of SMA on the background of gene therapy. A comparative analysis of the levels of light and heavy NF chains in the blood serum in SMA patients at the presymptomatic stage before gene therapy and 76 neurologically healthy children obtained in a recent study showed the level of light NF chains in SMA to be significantly higher (p < 0.001) — Me — 6.00, Q1; Q3 = 6.00; 31.43 pg/ml and Me — 4.00, Q1; Q3 = 2.50; 9.57 pg/ml, respectively. At the same time, the level of heavy NF chains did not significantly differ when comparing SMA patients at the presymptomatic stage before gene therapy with healthy peers. The use of onasemnogen abeparvovec in SMA patients at the presymptomatic stage led to a statistically significant decrease in the level of light chains NF in the blood serum. The maximum decrease in NF was observed 3–6 months after the gene therapy.Conclusion. Carrying out gene therapy using the onasemnogen abeparvovek in SMA patients at the presymptomatic stage made it possible to prevent the development of symptoms of the disease and achieve the main stages of motor development milestones according to WHO criteria.Compliance with ethical standards. Permission to conduct this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health (Minutes of the Local ethics committee, meeting No. 10 dated 10/06/2022).Contribution:Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A. — concept and design of research, writing, editing;Chernikov V.V. — statistical data processing, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: November 6, 2024Accepted: December 1, 2024Published: January 31, 2025
- Open Access
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 221-227
Oxidative phosphorylation deficiency type 10 is a rare cause of hypertrophic cardiomyopathy
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026
- 31 January 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (4) , 221-227
Open AccessOxidative phosphorylation deficiency type 10 is a rare cause of hypertrophic cardiomyopathy
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- Open Access
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 197-205
Glutamic acid, glutamate receptors, and nitric oxide in hypoxic brain damage
Introduction. Multifunctional glutamic acid (glutamate, Glu) is the main excitatory neurotransmitter in the central nervous system (CNS). By providing excitatory neurotransmission, Glu activates glutamate receptors (GluRc) associated with the intake of calcium (Ca2+). Acute and chronic Glu excitotoxicity and nitric oxide (NO) play a leading role in the mechanisms of neuron death during brain hypoxia, which accompanies cerebral circulatory disorders (CCD), strokes, epilepsy, traumatic brain injury (TBI), and neurodegenerative diseases. The aim of the study was to determine changes in the content of glutamic acid in the blood and cerebrospinal fluid (CSF) and the functional activity of GluRc receptors in children with various forms of hypoxic brain damage. Materials and methods. Seventy nine CCD newborns, 36 children with congenital hydrocephalus, 58 children with acute lymphoblastic leukemia complicated by neuroleukemia, 42 children with epilepsy and paroxysmal conditions, and 159 children with TBI were examined. The content of Glu, glutamine (Gln), ammonia and biochemical markers of hypoxia (glucose, lactate) were determined in CSF and blood in CCD newborns using enzyme methods. The content of autoantibodies to NMDA and AMP GluRc was determined by enzyme immunoassay methods. The content of NO and its transformation products was estimated by the total content of nitrites and nitrates using the Griss method. Results. As the severity of hypoxic brain damage increased, glucose levels decreased in the CSF of newborns, the content of lactate, protein, ammonia, and Glu increased, and the permeability of the brain-blood barrier increased. At the same time, the more pronounced brain damage was observed in children with various hypoxic CNS injuries, the higher the levels of Glu, total protein, and CA were observed in CSF. Conclusion. The established patterns allowed determining the importance of NO and its conversion products in the functional activity of GluRc and showing the involvement of NO in protective and damaging processes in brain tissue.
- 27 June 2025
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 28 (3) , 197-205
Open AccessGlutamic acid, glutamate receptors, and nitric oxide in hypoxic brain damage
Introduction. Multifunctional glutamic acid (glutamate, Glu) is the main excitatory neurotransmitter in the central nervous system (CNS). By providing excitatory neurotransmission, Glu activates glutamate receptors (GluRc) associated with the intake of calcium (Ca2+). Acute and chronic Glu excitotoxicity and nitric oxide (NO) play a leading role in the mechanisms of neuron death during brain hypoxia, which accompanies cerebral circulatory disorders (CCD), strokes, epilepsy, traumatic brain injury (TBI), and neurodegenerative diseases. The aim of the study was to determine changes in the content of glutamic acid in the blood and cerebrospinal fluid (CSF) and the functional activity of GluRc receptors in children with various forms of hypoxic brain damage. Materials and methods. Seventy nine CCD newborns, 36 children with congenital hydrocephalus, 58 children with acute lymphoblastic leukemia complicated by neuroleukemia, 42 children with epilepsy and paroxysmal conditions, and 159 children with TBI were examined. The content of Glu, glutamine (Gln), ammonia and biochemical markers of hypoxia (glucose, lactate) were determined in CSF and blood in CCD newborns using enzyme methods. The content of autoantibodies to NMDA and AMP GluRc was determined by enzyme immunoassay methods. The content of NO and its transformation products was estimated by the total content of nitrites and nitrates using the Griss method. Results. As the severity of hypoxic brain damage increased, glucose levels decreased in the CSF of newborns, the content of lactate, protein, ammonia, and Glu increased, and the permeability of the brain-blood barrier increased. At the same time, the more pronounced brain damage was observed in children with various hypoxic CNS injuries, the higher the levels of Glu, total protein, and CA were observed in CSF. Conclusion. The established patterns allowed determining the importance of NO and its conversion products in the functional activity of GluRc and showing the involvement of NO in protective and damaging processes in brain tissue.
- Open Access
- 30 April 2025
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (1) , 13-25
The efficacy of gene therapy with onasemnogene abeparvovec in spinal muscular atrophy in young patients
Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are largely limited due to the narrow criteria for selecting patients and the short duration of the following-up. Objective. To evaluate the efficacy of onasemnogene abeparvovec gene therapy in patients with SMA type I with clinical manifestations of the disease and in children at the presymptomatic stage of the disease in real clinical practice. Materials and methods. The study included seventy nine SMA children including 42 boys (53.2%). The diagnosis was verified during DNA diagnostics. The children were divided into two subgroups, depending on whether they had symptoms of SMA at the time of inclusion in the study or not. 44 children had SMA type I with the onset of clinical symptoms before the age of 6 months of life. 35 children were at the presymptomatic stage of the disease. All patients received gene therapy with onasemnogene abeparvovec, the average age at the moment of conduction of therapy was 2.90 ± 1.74 months (95% CI: 2.51–3.29 months), min — 1.00 month, max — 7.00 months. A comprehensive assessment of clinical parameters (stages of motor development milestones according to WHO recommendations, HINE-2 and CHOP-INTEND scores) was carried out before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results. Children with SMA type I showed favour trend in motor development milestones after gene therapy. By the end of the second year of the follow-up, 88.6% of patients held their head erect and rolled from back to sides; 60.5% could sit without support, but only 10.3% were able to achieve all motor skills, but none of these children achieved them in accordance with WHO criteria. The HINE-2 score increased from Me of 2.0 (1.00–2.25) points at the initiation of therapy to Me of 20.00 (16.50-24.50) points by the end of the follow-up period. Only two children (4.5%) of this subgroup reached the maximum score of 26 points. The CHOP-INTEND score increased from Me of 30.0 (22.00–37.25) points before starting treatment to Me of 60.0 (58.0-64.0) points by 24 months of follow-up. Only 11.4% of patients with SMA type I reached the maximum score of 64 points. The majority of the presymptomatic patients in our study achieved all motor development milestones according to WHO criteria according to their age on the background of gene therapy. All children from this subgroup who were under sufficient supervision and reached the age of walking alone (23 children) had a maximum HINE-2 score of 26 points by the age of 18 months. All children from this subgroup reached the maximum CHOP-INTEND score of 64 points by the age of 6 months. Conclusion. The usage of onasemnogene abeparvovec in children with SMA type I both significantly modifies the course of the disease and improves outcomes compared with the natural history of SMA course with early onset, and the usage of gene therapy in most of the presymptomatic patients leads to the achievement of motor development milestones in accordance with WHO criteria.
- 30 April 2025
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 6 (1) , 13-25
Open AccessThe efficacy of gene therapy with onasemnogene abeparvovec in spinal muscular atrophy in young patients
Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are largely limited due to the narrow criteria for selecting patients and the short duration of the following-up. Objective. To evaluate the efficacy of onasemnogene abeparvovec gene therapy in patients with SMA type I with clinical manifestations of the disease and in children at the presymptomatic stage of the disease in real clinical practice. Materials and methods. The study included seventy nine SMA children including 42 boys (53.2%). The diagnosis was verified during DNA diagnostics. The children were divided into two subgroups, depending on whether they had symptoms of SMA at the time of inclusion in the study or not. 44 children had SMA type I with the onset of clinical symptoms before the age of 6 months of life. 35 children were at the presymptomatic stage of the disease. All patients received gene therapy with onasemnogene abeparvovec, the average age at the moment of conduction of therapy was 2.90 ± 1.74 months (95% CI: 2.51–3.29 months), min — 1.00 month, max — 7.00 months. A comprehensive assessment of clinical parameters (stages of motor development milestones according to WHO recommendations, HINE-2 and CHOP-INTEND scores) was carried out before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results. Children with SMA type I showed favour trend in motor development milestones after gene therapy. By the end of the second year of the follow-up, 88.6% of patients held their head erect and rolled from back to sides; 60.5% could sit without support, but only 10.3% were able to achieve all motor skills, but none of these children achieved them in accordance with WHO criteria. The HINE-2 score increased from Me of 2.0 (1.00–2.25) points at the initiation of therapy to Me of 20.00 (16.50-24.50) points by the end of the follow-up period. Only two children (4.5%) of this subgroup reached the maximum score of 26 points. The CHOP-INTEND score increased from Me of 30.0 (22.00–37.25) points before starting treatment to Me of 60.0 (58.0-64.0) points by 24 months of follow-up. Only 11.4% of patients with SMA type I reached the maximum score of 64 points. The majority of the presymptomatic patients in our study achieved all motor development milestones according to WHO criteria according to their age on the background of gene therapy. All children from this subgroup who were under sufficient supervision and reached the age of walking alone (23 children) had a maximum HINE-2 score of 26 points by the age of 18 months. All children from this subgroup reached the maximum CHOP-INTEND score of 64 points by the age of 6 months. Conclusion. The usage of onasemnogene abeparvovec in children with SMA type I both significantly modifies the course of the disease and improves outcomes compared with the natural history of SMA course with early onset, and the usage of gene therapy in most of the presymptomatic patients leads to the achievement of motor development milestones in accordance with WHO criteria.
- Open Access
- 13 October 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (3) , 165-174
SCN8A epileptic encephalopathy: literature review and own observation
A genetic disease caused by pathogenetic nucleotide variants in the SCN8A gene (Sodium channel protein type 8 subunit alpha, also known as Nav1.6), encoding the α-subunit of the Na channel type 8, is included in the group of early epileptic encephalopathies. In most cases, this pathology is characterized by the development of polymorphic pharmacoresistant epileptic seizures over the first year of a child’s life, a lag in psychomotor development or regression, loss of skills. In some patients, seizures may appear during the first days of life, while in others they appear later (at the age of 2 to 7 months), against the background of a pronounced or slight developmental delay. Types of seizures may include generalized, tonic-clonic seizures, infantile spasms, absences and focal seizures. Other signs and symptoms of encephalopathy caused by mutations of the SCN8A gene may include low muscle tone (hypotension), high pain threshold, motor disorders (such as dystonia and ataxia), mild to severe mental retardation, sleep problems and autistic traits. In some people with SCN8A encephalopathy, various other pathological changes in the body have been reported, including hearing or vision impairment, scoliosis, and thermoregulation difficulties. The disease is inherited by an autosomal dominant type. To date, the disease in the OMIM system is referred to as «Developmental encephalopathy and epileptic encephalopathy type 13». Previously, the disease was called «Early infantile (infantile) epileptic encephalopathy, type 13». The serial number «13» indicates this form of early epileptic encephalopathy to be caused by a heterozygous mutation in the gene on the long arm of chromosome 12 in chromosome region 12q13.13. This report also presents a clinical description of a patient suffering from early infantile epileptic encephalopathy, type 13.
- 13 October 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (3) , 165-174
Open AccessSCN8A epileptic encephalopathy: literature review and own observation
A genetic disease caused by pathogenetic nucleotide variants in the SCN8A gene (Sodium channel protein type 8 subunit alpha, also known as Nav1.6), encoding the α-subunit of the Na channel type 8, is included in the group of early epileptic encephalopathies. In most cases, this pathology is characterized by the development of polymorphic pharmacoresistant epileptic seizures over the first year of a child’s life, a lag in psychomotor development or regression, loss of skills. In some patients, seizures may appear during the first days of life, while in others they appear later (at the age of 2 to 7 months), against the background of a pronounced or slight developmental delay. Types of seizures may include generalized, tonic-clonic seizures, infantile spasms, absences and focal seizures. Other signs and symptoms of encephalopathy caused by mutations of the SCN8A gene may include low muscle tone (hypotension), high pain threshold, motor disorders (such as dystonia and ataxia), mild to severe mental retardation, sleep problems and autistic traits. In some people with SCN8A encephalopathy, various other pathological changes in the body have been reported, including hearing or vision impairment, scoliosis, and thermoregulation difficulties. The disease is inherited by an autosomal dominant type. To date, the disease in the OMIM system is referred to as «Developmental encephalopathy and epileptic encephalopathy type 13». Previously, the disease was called «Early infantile (infantile) epileptic encephalopathy, type 13». The serial number «13» indicates this form of early epileptic encephalopathy to be caused by a heterozygous mutation in the gene on the long arm of chromosome 12 in chromosome region 12q13.13. This report also presents a clinical description of a patient suffering from early infantile epileptic encephalopathy, type 13.
- Open Access
- 30 June 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (2) , 104-114
The debut and course of the neonatal form of propionic aciduria: a clinical case
Propionic aciduria (PA) is an autosomal recessive hereditary disease from the group of organic aciduria, caused by a deficiency of propionyl-CoA carboxylase, leading to impaired metabolism of methionine, threonine, valine, isoleucine, and fatty acids with an odd number of carbon atoms and cholesterol. The neonatal form of PA manifests itself during the first week of life, is characterized by an acute onset and a crisis course, which is accompanied by severe metabolic acidosis, hypoglycemia, hyperketonemia, hyperammonemia. Clinical symptoms are dominated by neurological disorders up to stupor or coma, which can lead to death. Since 2023, expanded neonatal screening has been introduced throughout the Russian Federation, which includes 36 groups of nosologies, as well as a number of hereditary metabolic diseases. Despite the inclusion of this pathology in expanded neonatal screening, doctors’ awareness of clinical manifestations and necessary therapy remains insufficient. Often such patients are diagnosed with, for example: hypoxic-ischemic damage to the central nervous system, acute meningoencephalitis, and others, which leads to inadequate therapy with the development of fatal neurological consequences. Therefore, the totality of knowledge and alertness of doctors regarding diseases from the group of hereditary metabolic diseases will help not only to suspect this pathology in a timely manner, but also to prescribe adequate therapy in time, which in the future will make it possible to prevent serious consequences and neurological disorders, as well as disability of patients.
- 30 June 2023
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 4 (2) , 104-114
Open AccessThe debut and course of the neonatal form of propionic aciduria: a clinical case
Propionic aciduria (PA) is an autosomal recessive hereditary disease from the group of organic aciduria, caused by a deficiency of propionyl-CoA carboxylase, leading to impaired metabolism of methionine, threonine, valine, isoleucine, and fatty acids with an odd number of carbon atoms and cholesterol. The neonatal form of PA manifests itself during the first week of life, is characterized by an acute onset and a crisis course, which is accompanied by severe metabolic acidosis, hypoglycemia, hyperketonemia, hyperammonemia. Clinical symptoms are dominated by neurological disorders up to stupor or coma, which can lead to death. Since 2023, expanded neonatal screening has been introduced throughout the Russian Federation, which includes 36 groups of nosologies, as well as a number of hereditary metabolic diseases. Despite the inclusion of this pathology in expanded neonatal screening, doctors’ awareness of clinical manifestations and necessary therapy remains insufficient. Often such patients are diagnosed with, for example: hypoxic-ischemic damage to the central nervous system, acute meningoencephalitis, and others, which leads to inadequate therapy with the development of fatal neurological consequences. Therefore, the totality of knowledge and alertness of doctors regarding diseases from the group of hereditary metabolic diseases will help not only to suspect this pathology in a timely manner, but also to prescribe adequate therapy in time, which in the future will make it possible to prevent serious consequences and neurological disorders, as well as disability of patients.